Identifying Mechanisms of Resistance to mTOR Inhibitors in Cancer

Trial Profile

Identifying Mechanisms of Resistance to mTOR Inhibitors in Cancer

Discontinued
Phase of Trial: Phase I

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Cancer
  • Focus Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Apr 2016 Status changed from active, no longer recruiting to discontinued.
    • 20 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Feb 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top